FDA Approves Lilly Cancer Drug Combo

The US FDA approved Eli Lilly's drug combination to treat adults with advanced breast cancer. The therapy combines Inluriyo and Verzenio to help patients whose cancer has progressed after hormone treatment.

Xurve View
Insights:
FILE PHOTO: A drone view shows the Eli Lilly logo on one of the company’s offices after it hit $1 trillion in market value on Friday, becoming the first drugmaker to join the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse, in San Diego, California, U.S., November 21, 2025. REUTERS/Mike Blake/File Photo

Eli Lilly & Co has won U.S. Food and Drug Administration approval for a new drug combination to treat advanced breast cancer. The treatment targets adult patients with metastatic disease carrying an ESR1 mutation.